Molecular Docking Studies of Selected Inhibitors of β-cell Lymphoma-2 Family Proteins


  • David E. Arthur Department of Chemistry, University of Maiduguri, Maiduguri, Nigeria
  • Augustina O. Aroh Department of Chemistry, Ahmadu Bello University, Zaria, Nigeria
  • Stanley I.R. Okoduwa Department of Biochemistry, School of Basic Medical Sciences, Babcock University, Ilishan-Remo, Nigeria
  • Umar T. Mamza Department of Chemistry, University of Maiduguri, Maiduguri, Nigeria



Cancer, B-cell lymphoma 2 (BCL-2), Docking analysis, Binding affinity, SBDD


Thirty-six compounds obtained from the PubChem database were used to study the inhibition of BCL-2 receptor through a computational-aided drug-design technique. The molecular docking of all the ligands was evaluated for binding to BCL-2 protein (apoptosis regulator). All the selected chemical datasets were drawn with Chemdraw program and docked within the binding pocket of BCL-2 using ICM-pro molsoft software. The structures of AP7 and AP26 were modified to form new compounds designated AP7a and AP26a respectively. The binding energies of AP7a and AP26a were determined as well as those of the thirty-six lead compounds. Ligands AP7 (-25.313 kcal/mol) and AP26 (-29.430 kcal/mol) were the best of all the 36 compounds. A notable improvement was seen in the binding pose of the modified compounds where the result of the binding energy values of AP7a and AP26a was found to be -25.264 kcal/mol and -26.0851kcal/mol respectively. The number of hydrogen bonds found in AP7a was significantly more than its parent lead. These bonds were formed between the compound and the following amino acids: ARG139 (2.05Å), TRY180 (1.55Å), LEU59 (1.76Å), GLU135 (2.63Å) and ARG139 (1.82Å).The binding pose of AP26a was found to have seven hydrogen bonds: HIS120 (2.13Å), ARG129 (1.72Å), Leu59 (1.98 Å), SER60 (2.64 Å), LYS58 (2.63), GLN118 (1.95 Å) and THR132 (2.54Å).The aforementioned results showed that the newly designed compounds were better BCL-2 apoptosis regulator inhibitors compared with the 36 compounds used for the study, due to the significant hydrogen bond energies formed by the novel compounds.


Download data is not yet available.


Abdullahi, M., Uzairu, A., Shallangwa, G. A., Arthur, D. E., Umar, B. A., and Ibrahim, M. T. (2020). Virtual molecular docking study of some novel carboxamide series as new anti-tubercular agents.European Journal of Chemistry, 11(1), 30-36.

Adams, C. M., Clark-Garvey, S., Porcu, P., and Eischen, C. M. (2019). Targeting the Bcl-2 family in B-cell lymphoma. Frontiers in Oncology, 8, 636.

Adams, J. M., and Cory, S. (2001). Life-or-death decisions by the Bcl-2 protein family.Trends in Biochemical Sciences, 26(1), 61-66.

Adeniji, S. E., Arthur, D. E., and Oluwaseye, A. (2020). Computational modeling of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent anti-diabetic agent against Tgr5 receptor.Journal of King Saud University-Science, 32(1), 102-115.

Antignani, A., and Youle, R. J. (2006). How do bax and bak lead to permeabilization of the outer mitochondrial membrane? Current Opinion in Cell Biology, 18(6), 685-689.

Arthur, D. E. (2019). Molecular docking studies of some topoisomerase ii inhibitors: implications in designing of novel anticancer drugs. Radiology of Infectious Diseases, 6(2), 68-79.

Arthur, D. E. and Uzairu, A. (2018). Molecular docking study and structure‐based design of novel camptothecin analogues used as topoisomerase I inhibitor. Journal of the Chinese Chemical Society, 65(10), 1160-1178.

Arthur, D. E., Akoji, J. N., Sahnoun, R., Okafor, G. C., Abdullahi, K. L., Abdullahi, S. A., and Mgbemena, C. (2021). A theoretical insight in interactions of some chemical compounds as mtor inhibitors. Bulletin of the National Research Centre, 45(1), 1-12.

Arthur, D. E., Elegbe, B. O., Aroh, A. O., and Soliman, M. (2022). Computational drug design of novel covid-19 inhibitor. Bulletin of the National Research Centre, 46(1), 1-29.

Basu, A. (2021). The interplay between apoptosis and cellular senescence: bcl-2 family proteins as targets for cancer therapy. Pharmacology and Therapeutics, 230, 107943.

Becke, A. D. (1993). Density‐functional thermochemistry. iii. the role of exact exchange. Journal of Chemical Physics ,98(7), 5648-5652.

Bertram, K., Leary, P. J., Boudesco, C., Fullin, J., Stirm, K., Dalal, V., Zenz, T., Tzankov, A. and Müller, A. (2022). Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models. Leukemia, 36(4), 1035–1047.

Brogi, S., Ramalho, T.C., Kuca, K., Medina-Franco, J.L. and Valko, M. (2020). In silicomethods for drug design and discovery.Frontiers in Chemistry, 8, 612

Choudhary, M. and Sharma, B. K. (2014). Qsar Rationales for the 5-Ht6 Antagonistic activity of epiminocyclohepta [B] Indoles. Journal of Pharmaceutical Chemistry, 6, 321-330.

Enyedy, I. J., Ling, Y., Nacro, K., Tomita, Y., Wu, X., Cao, Y., Guo, R., Li, B., Zhu, X., Huang, Y., Long, Y. Q., Roller, P. P., Yang, D. and Wang, S. (2001). Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. Journal of Medicinal Chemistry, 44(25), 4313–4324.

He, W., Li, X., Morsch, M., Ismail, M., Liu, Y., Rehman, F. U., Zhang, D., Wang, Y., Zheng, M., Chung, R., Zou, Y., & Shi, B. (2022). Brain-targeted codelivery of Bcl-2/Bcl-xl and Mcl-1 inhibitors by biomimetic nanoparticles for orthotopicglioblastoma therapy. ACS Nano, 16(4), 6293–6308.

Ku, B., Liang, C., Jung, J. U., and Oh, B.-H. (2011). Evidence that Inhibition of BAX activation by Bcl-2 involves its tight and preferential interaction with the Bh3 domain of BAX. Cell Research, 21(4), 627-641.

Larif, M., Chtita, S., Adad, A., Hmamouchi, R., Bouachrine, M., and Lakhlifi, T. (2013). Predicting biological activity of anticancer molecules 3-Ary L-4-hydroxyquinolin-2-(1h)-One by Dft-Qsar Models. International Journal of Cancer, 3(12).

Lee, C., Yang, W. and Parr, R. G. (1988). Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Physics Review. B, Condensed Matter, 37(2), 785–789.

MolSoft, I. (2000). 2.8 Program manual. San Diego, CA: MolSoft LLC.

Molsoft, L. L. C. "ICM-browser." MolsoftInc, San Diego (2017).

Neves, M. A., Totrov, M., and Abagyan, R. (2012). Docking and scoring with ICM: the benchmarking results and strategies for improvement. Journal of Computer-aided Molecular Design, 26(6), 675-686.

Patterson, C. M., Balachander, S. B., Grant, I., Pop-Damkov, P., Kelly, B., McCoull, W., Parker, J., Giannis, M., Hill, K. J., Gibbons, F. D., Hennessy, E. J., Kemmitt, P., Harmer, A. R., Gales, S., Purbrick, S., Redmond, S., Skinner, M., Graham, L., Secrist, J. P., Schuller, A. G., Wen, S., Adam, A., Reimer, C., Cidado, J., Wild, M., Gangl, E., Fawell, S. E., Saeh, J., Davies, B. R., Owen, D. J. and Ashford, M. B. (2021). Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Communications Biology, 4(1), 112.

Phillips, J. C., Hardy, D. J., Maia, J. D. C., Stone, J. E., Ribeiro, J. V., Bernardi, R. C., Buch, R., Fiorin, G., Hénin, J., Jiang, W., McGreevy, R., Melo, M. C. R., Radak, B. K., Skeel, R. D., Singharoy, A., Wang, Y., Roux, B., Aksimentiev, A., Luthey-Schulten, Z., Kalé, L. V., Schulten, K., Chipot, C. and Tajkhorshid, E. (2020). Scalable molecular dynamics on CPU and GPU architectures with NAMD. The Journal of Chemical Physics, 153(4), 044130.

Rooswinkel, R.W., Van-de Kooij, B., de Vries, E., Paauwe, M., Braster, R., Verheil, M., and Borst, J. (2014). Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity. Blood, The Journal of American Society of Hermatology, 123(18), 2806-2815

Scarpino, A., Ferenczy, G. r. G., and Keserű, G. r. M. (2018). Comparative evaluation of covalent docking tools.Journal of Chemical Information and Modeling, 58(7), 1441-1458.

Singh, R., Letai, A., and Sarosiek, K. (2019). Regulation of apoptosis in health and disease: The balancing act of Bcl-2 family proteins. Nature Reviews Molecular Cell Biology, 20(3), 175-193.

Speck-Planche, A., Kleandrova, V. V., Luan, F., and Cordeiro, M. N. D. (2012). Rational drug design for anti-cancer chemotherapy: multi-target QSAR models for the in silico discovery of anti-colorectal cancer agents. Bioorganic and Medicinal Chemistry, 20(15), 4848-4855.

Thomsen, R. and Christensen, M.H. (2006). MolDock: A new technique for high-accuracy molecular docking. Journal of Medicinal Chemistry, 49(11), 3315-3321

Tinworth, C.P., and Young, R.J. (2020). Facts, patterns, and principles in drug discovery: Appraising the rule of 5 with measured physicochemical data. Journal of Medicinal Chemistry, 63(18), 10091-10108

Warren, C. F., Wong-Brown, M. W., and Bowden, N. A. (2019). Bcl-2 family isoforms in apoptosis and cancer.Cell Death and Disease, 10(3), 1-12.

Zhang, J. (2009). Studies on the structural stability of rabbit prion probed by molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 27(2), 159-162.

Zhang, Q., Riley-Gillis, B., Han, L., Jia, Y., Lodi, A., Zhang, H., Sweeney, S. R. (2022). Activation of Ras/Mapk pathway confers Mcl-1 mediated acquired resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduction and Targeted Therapy, 7(1), 1-13



How to Cite

Arthur, D. E. ., Aroh, A. O. ., Okoduwa, S. I. ., & Mamza, U. T. . (2022). Molecular Docking Studies of Selected Inhibitors of β-cell Lymphoma-2 Family Proteins. Nigerian Journal of Biochemistry and Molecular Biology, 37(4), 241–256.